These data support the effectiveness of rucaparib as a potent PARPi for radiosensitizing PCa cells, particularly those that express the TMPRSS2-ERG gene fusion and are PTEN-deficient, indicating potential clinical application for brachytherapy in patients with intermediate and high risk PCa. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.